EP2066657A1 - Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine - Google Patents

Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine

Info

Publication number
EP2066657A1
EP2066657A1 EP07802882A EP07802882A EP2066657A1 EP 2066657 A1 EP2066657 A1 EP 2066657A1 EP 07802882 A EP07802882 A EP 07802882A EP 07802882 A EP07802882 A EP 07802882A EP 2066657 A1 EP2066657 A1 EP 2066657A1
Authority
EP
European Patent Office
Prior art keywords
alkylene
alkyl
group
general formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07802882A
Other languages
German (de)
English (en)
Inventor
Hervé Geneste
Thorsten Oost
Astrid Netz
Charles W. Hutchins
Wolfgang Wernet
Wolfgang Lubisch
Liliane Unger
Wilfried Hornberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of EP2066657A1 publication Critical patent/EP2066657A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the present invention relates to novel substituted oxindole derivatives, medicaments containing them and their use for the treatment of diseases.
  • Vasopressin is an endogenous hormone that has a variety of effects on organs and tissues. In various disease states, it is believed that the vasopressin system plays a role, such as heart failure and hypertension.
  • three receptors V1a, V1b and V3 and V2 are known, through which vasopressin mediates its numerous effects. Therefore, antagonists of these receptors are being investigated as potential new therapeutic approaches to the treatment of disease (M. Thibonnier, Exp. Olpin Invest. Drugs 1998, 7 (5), 729-740).
  • Oxytocin is a hormone produced in neurosecretory neurons of the hypothalamus and, bound to neurophysins, transported to the pituitary backbone and stored there. Oxytocin stimulates the contraction of the uterine musculature and the myoepithelial cells of the mammary gland (milk injection); the uterine contractility is varied by estrogens (promoting effects) and progestagens (inhibitory effects). Oxytocin is degraded by the enzyme oxytocinase. Oxytocin is used in obstetrics (e.g., for labor induction, postpartum uterine atony) (cited: Roche Lexicon Medicine 5th Edition).
  • novel substituted oxindoles which carry an aryl-sulfonyl group in the 1-position.
  • 1-phenylsulfonyl-1,3-dihydro-2H-indole-2-ones have already been described as ligands of vasopressin receptors.
  • WO 93/15051, WO 95/18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/164668 and WO 01/98295 describe derivatives which are derived from the oxindole skeleton and in the 1-position Arylsulfonly deficit bear. These compounds differ significantly in the substitution in the 3-position.
  • WO 93/15051 and WO 98/25901 describe 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones as ligands of the vasopressin receptors in which the oxindole skeleton is in the 3-position by two alkyl radicals substituted, which may also be a cycloalkyl radical (spiro linkage).
  • the spiro ring may contain heteroatoms such as oxygen and nitrogen (optionally with substituents).
  • WO 95/18105 describes 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones as ligands of vasopressin receptors having a nitrogen atom in the 3-position.
  • radicals are attached in the 3-position, which may be alkyl, cycloalkyl, phenyl or benzyl radicals (each optionally with substituents).
  • WO 03/008407 describes 1-phenylsulfonyloxindoles in which pyridylpiperazines are bonded to the oxindole via an oxycarbonyl group in the 3-position.
  • the object of the present invention is to provide further compounds for the treatment or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases which have a high and selective activity, preferably in particular over the vasopressin V 16 receptor.
  • a C ⁇ -C-io-Ary! is that with one, two, three or four residues selected from the
  • R A 1 , R A 2 , R A 3 and / or R A 4 may be substituted, wherein R A 1 , R A 2 , R A 3 and R A 4 are independently selected and independently of their occurrence from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, in each case optionally substituted ORA 5 , CORA 5 , COOR A 5 , SR A 5 , C 3 -C 7 -cycloalkyl, OCOR A 5 , SO 2 NR A A 6 R 7, CONR 6 R A A 7, C 0 -C 4 -alkylene-CN, Ci-C 6 haloalkyl, -C 6 haloalkoxy, NO 2, C 0 -C 4 -alkylene-OR 5 A, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkenyloxy, C 2 -C 6
  • Alkylene CONH (C 1 -C 4 -alkyl), NHCOCH 3 , NO 2 , (CH 2 ) o-2- OH, OC r C 6 -alkyl, (CH 2 ) 0-2 -O-Ci-C 4 -alkyl, 0-C o -C 4 -alkylene-phenyl, phenyl,
  • R A 5 independently of its respective occurrence hydrogen, a branched or unbranched radical dC 6 alkyl, or a branched or unbranched, optionally substituted radical C 2 -C 6 alkenyl, C 2 -C ⁇ alkynyl, C 3 -C 7 cycloalkyl, Ci-C 4 -alkylene-C 3 -C 7 cycloalkyl or C r C 4 alkylene
  • R A 6 and R A 7 independently of one another and independently of their occurrence hydrogen, a branched or unbranched, optionally substituted radical dC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, dd- Alkylene-dd-alkoxy, C 3 -C 7 -cycloalkyl, C r C 4 -alkylene-C 3 -C 7 -cycloalkyl, Ci-C 4 -alkylene-aryl, or a radical -SO 2 R A 5 , -CO 2 R A 5 , -CO-NR A 5 R A 5 , or - COR A 5 , or together with the nitrogen atom to which they are bonded, for a 3-, 4-, 5-, 6- or 7-membered, saturated or unsaturated nitrogen heterocycle, which may have another heteroatom from the group O, S and NR A 76 and which is unsubstituted and / or 1, 2, 3 or 4 substituents
  • an aromatic or partly aromatic C 6 -C 0 is mono- or anellated bicyclo which has up to four radicals selected from the group consisting of R B1, R B2, R B3, R 6 and 4 may be substituted, R 6 1 , R B 2 , R B 3 and R 6 4 are independently of one another and independently of their respective occurrence selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, OR 6 5 ,
  • R 6 regardless of its respective occurrence hydrogen, a branched or unbranched, optionally substituted -C 6 alkyl, C 2 - Ce alkenyl, C 2 -C 6 alkynyl, Ci-C 5 alkylene-C 4 alkoxy, mono- or bis- (C r -C 6) - alkylamino (CrC 4) -alkylene or (Ci-C 6) acylamino (Ci-C 4) alkylene radical or an optionally substituted (C 6 -C 0) aryl, Cs-Cr heterocycloalkyl, C 3 - Cr-heterocycloalkenyl, (C 3 -C 0) hetaryl, C 3 -C 7 cycloalkyl, C r C 4 -alkylene-C 3 -
  • C 7 cycloalkyl Ci-C 4 -alkylene- (C 6 -C 0) aryl, C r C 4 alkylene C 3 -C 7 - heterocycloalkyl, dC 4 alkylene Cs-C T -Heterocyloalkenyl - or C 1 -C 4 -alkylene (C 2 -C 10) -hetaryl,
  • R 6 6 and R 6 7 independently and independently of their respective
  • Occurrence is hydrogen, a branched or unbranched, optionally substituted dC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C 5 - alkylene-dC 4 alkoxy, mono- or bis- ( Ci-C 6) alkylamino (C- ⁇ -C 4) alkylene or (CrC 6) acylamino (Ci-C 4) alkylene radical or an optionally substituted (C 6 -C 0) aryl -, Cs-C ⁇ -1-leterocycloalkyl-, C 3 -C 7 -
  • R 6 6 and R 6 7 independently of their respective occurrence together a 3 to 7-membered, optionally substituted, or preferably with CrC ⁇ -alkyl, OMe, halogen-substituted, saturated, unsaturated or aromatic heterocycle which in addition to the ring nitrogen atom up to three further different or identical heteroatoms selected from the group consisting of O, N and S may contain, and optionally two substituted on this heterocycle radicals R x and R x together a fused, saturated, unsaturated or aromatic carbocycle or heterocycle, up to three different or like heteroatoms selected from
  • R 1 and R 2 independently of one another are hydrogen, Br, F, Cl, J, C 4 -alkylene-CN, CN, Ci-C 6 haloalkyl, Ci-C 6 haloalkoxy, NO 2, C 4 - alkylene OR ⁇ 1, OR x 1, 0-Ci-C4-alkylene- ( C 6 -Cio) aryl, O- (C 6 -C 0) aryl, 0-C r C 4 - alkylene-hetaryl, O-hetaryl, Ci-C 4 -alkylene- (C 6 -C 0) - aryl, (C 6 -C 0) aryl, Ci-C 4 - alkylene-hetaryl, (C 2 -C 0) hetaryl, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 - Ce-alkenyloxy, C 2 -C 6
  • R x 1 independently of its occurrence hydrogen, a branched or unbranched, optionally substituted radical dC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 5 alkylene CrC 4 alkoxy, mono- or bis- (C r C6) - alkylamino (Ci-C 4) alkylene or (CrC 6) acylamino (Ci-C4) alkylene or an optionally substituted (C 6 -C 0) aryl, Cs-C ⁇ -1-leterocycloalkyl-, C 3 -C 7 - heterocycloalkenyl, (C2 -Cio) hetaryl, C 3 -C 7 cycloalkyl, C r C 4 - alkylene-C 3 -C 7 - cycloalkyl, Ci-C 4 -alkylene- (C 6 -C 0) aryl, C r C 4
  • R x and R x 2 3 independently of each other and independently of their respective occurrence hydrogen, a branched or unbranched, optionally substituted radical C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 5 -alkylene-C 1 -C 4 -alkoxy, mono- or bis (C 1 -C 6 ) -alkylamino- (C 1 -C 4 ) -alkylene- or (C 1 -C 6 ) -
  • R 1 and R 2 are independently hydrogen or an unsubstituted or mono-, di- or trisubstituted by identical or different substituents ⁇ - or 6-membered aromatic heterocycle having 1, 2, 3 or 4 heteroatoms selected from the group consisting from N, O and S, wherein the aromatic heterocycle may have one, two or three substituents R x 1 independently of one another and independently of their respective
  • Occurrence are selected from the group consisting of the radicals hydrogen, Br, F, Cl, I, C r C 4 -alkylene-CN, CN, C r C 6 haloalkyl, C r C 6 - haloalkoxy, NO 2, CrC 4 alkylene-OR x 1, x OR 1, O-Ci-C4-alkylene- (C 6 -C 0) aryl, O- (C 6 -C 0) aryl, OC r C 4 alkylene-hetaryl , O-hetaryl, Ci-C 4 -alkylene- (C 6 -C 0) - aryl, (C 6 -C 0) aryl, C r C 4 alkylene-hetaryl, (C 2 -C 0) hetaryl , C r C 6 alkyl, C 2 -C 6 -
  • R y is the general formula
  • R ⁇ 1 , R ⁇ 2 , R ⁇ 3 , R ⁇ 4 , R ⁇ 5 and R ⁇ 6 are independently selected from the group consisting of H, C 1 -C 6 -alkyl or C 3 -C 7 -cycloalkyl,
  • n is the integer 1, 2 or 3
  • n is the integer O, 1, 2 or 3,
  • radical R ⁇ 1 having one of the radicals R ⁇ 2 and R ⁇ 3, in each case together with the N or C atom to which they are bonded, is a saturated or unsaturated 4-, 5-, 6- or 7- resulting in a monocyclic ring;
  • radical R ⁇ 1 with one of the radicals R ⁇ 4 , R ⁇ 5 or R ⁇ 6 each together with the N or C atom to which they are attached, a saturated or unsaturated 4-, 5-, 6 or 7-membered monocyclic ring;
  • radical R ⁇ 1 with one of the radicals R ⁇ 2 and R ⁇ 3 together with the N or C atom to which they are attached, a saturated or unsaturated 4-, 5-, 6- or 7-membered monocyclic Ring and additionally one or two of the radicals R ⁇ 1 and R ⁇ 2 with one or two of the radicals R ⁇ 4 , R ⁇ 5 or R ⁇ 6 each together with the N or C atom to which they are attached, see above to form a total saturated or unsaturated bicyclic or tricyclic ring skeleton having 4-, 5-, 6- and / or 7-membered ring members;
  • the radical R ⁇ 1 having one of the radicals R ⁇ 4 , R ⁇ 5 or R ⁇ 6, in each case together with the N or C atom to which they are bonded is a saturated or unsaturated four, five, six or seven-membered monocyclic ring and additionally one or two of the radicals R ⁇ 1 and R ⁇ 2 with one or two of the radicals R ⁇ 4 , R ⁇ 5 or R ⁇ 6 in each case together with the N or C atom to which they are attached are linked together to form a total saturated or unsaturated bicyclic or tricyclic ring skeleton having 4-, 5-, 6- and / or 7-membered ring members;
  • the thus formed 4-, 5-, 6- or 7-membered, saturated or unsaturated mono-, bi- or tricyclic ring or the ring skeleton with 4-, 5-, 6- and / or 7-membered ring members additionally another heteroatom selected from the group consisting of O, S and NR ⁇ 5 may have as a ring member, wherein R YY 5 independently of its occurrence for hydrogen, dC 4 alkyl or C 3 -C 7 cycloalkyl may stand, and wherein the thus formed 4-, 5-, 6- or 7-membered, saturated or unsaturated mono-, bi- or tricyclic ring or the ring skeleton with 4-, 5-, 6- and / or 7-membered ring members one or may have two substituents R ⁇ 6 and R ⁇ 7 which are selected independently of one another and independently of their respective occurrence from the group consisting of the radicals dC 6 -
  • Alkyl, C 1 -C 6 -alkoxy, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkoxy, oxo (-C O), CN, OR ⁇ 8 , NR ⁇ 9 R ⁇ Y 10 , C 1 -C 6 -alkylene NR ⁇ 9 R ⁇ 10 , SO 2 NR ⁇ 9 R ⁇ Y 10 , CONR ⁇ 9 R ⁇ 10 and halogen;
  • OZ is a 5- or 6-membered, saturated or fully or partially unsaturated heterocycle or aromatic heteroaryl ring having 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle or heteroaryl ring one, two or three identical or different substituents R 2 may have 1, 5 which are independent from each other and independently of their respective occurrence selected from the group consisting of residues 6 -alkyl, -C 6 haloalkyl, d-Ce Alkyloxy, CF 3 , CH
  • Rz 1 , Rz 2 , Rz 3 , Rz 4 , Rz 5 and Rz 6 are independently of one another and independently of their occurrence selected from the group consisting of H, optionally substituted dC 6 alkyl, optionally substituted C 3 -C 7 -
  • Rz 7 independently of its occurrence H, OH, C 1 -C 6 -alkyl, C 1 -C 5 -alkoxy, C 3 -C 7 -cycloalkyl, CH 2 CH 2 COOH, NR 2 10 R 2 11 , preferably H, CH 3 , C 2 H 5 , iso -propyl, cyclohexyl, -CH 2 CH 2 COOH, NH 2 , N (CH 3 ) 2 ;
  • Rz Rz 8 and 9 are independently of each other and their respective occurrence selected from the group consisting of H, dC 6 alkyl and C 3 -C 6 cycloalkyl; or R 2 8 and R z 9 independently of their respective occurrence together with the nitrogen atom, a ring selected from the group consisting of
  • Rz 10 regardless of its occurrence H, dC 6 alkyl, or C 3 -C 6 -
  • Rz 3 may, irrespective of its occurrence, also denote a group COR Z 12 , where R z 12 is independent of its occurrence for
  • Carbocycle can form, which may have a heteroatom selected from the group consisting of O, S, and NR 2 13 , as a ring member, wherein R 2 is 13 for
  • p is independently of its occurrence the integer 1 or 2;
  • Each of the above-mentioned definitions of a variable may be combined with any of the definitions of the remaining variables mentioned above. This is especially true for the combination of preferred definitions of a variable with any or preferred definitions of the remaining variables.
  • At least one compound of general formula (I) is carried out as above or according to claim 1, wherein R 1 , R 2 , A and Y, unless otherwise specified below, have the abovementioned meanings and
  • B is a phenyl ring which may be substituted with one or two identical or different radicals which are independently selected from the group consisting of chlorine, bromine, iodine, fluorine, CN, CF 3, OCF 3, C r C 6 alkoxy , d-Ce-haloalkoxy, Ci-C 6 haloalkyl, NH 2, NH- (CrC 6 alkyl), N (-C 6 - alkyl) (C r C 6 alkyl), C r C 6 alkyl, C C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 2 -C 6 -alkenyloxy, C 2 -C 6 -alkynyloxy, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkoxy, halogenated C 3 -C 6 - cycloalkyl and halogenated C 3 -C 6 cycloal
  • substituent on B this is preferably located in the 2-position or the 4-position of the phenyl ring.
  • substituents on B they are preferably located in the 2- and the 4-position or in the 2- and the 5-position of the phenyl ring.
  • At least one compound of general formula (I) is carried out as above or according to claim 1 or 2, wherein R 1 , R 2 , A and Y, unless otherwise specified below, have the abovementioned meanings and
  • B is a phenyl ring which may be substituted with one or two identical or different radicals which are independently selected from the group consisting of hydrogen, chlorine, fluorine, CN, CH 3 , OCH 3 , NH 2 , NHCH 3 ,
  • B is a radical selected from the group consisting of phenyl, 2-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2-methoxy-4-methylphenyl, 2-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methoxy-5-fluorophenyl, 2-methoxy-5-methylphenyl, 2-methoxy-4-methoxyphenyl, 2-iso-butoxy-5- methoxyphenyl, 2-ethoxy-5-ethylphenyl, 2-ethoxy-4-methoxyphenyl and 4-cyano-phenyl,
  • At least one compound of the general formula (I) is carried out as described above, wherein R 1 , R 2 , A and Y, unless otherwise stated below, have the abovementioned meanings and
  • At least one compound of general formula (I) is carried out as above, wherein B, A and Y, unless otherwise specified below, have the abovementioned meanings and R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, F, Cl, Br, J, CN, C r C 6 alkyl, -OC r C 6 alkyl, C 3 -C 6 cycloalkyl , -O-Cs-Ce-cycloalkyl, halogenated O-C 6 alkyl, halogenated dC 6 alkyl, halogenated C 3 -C 6 cycloalkyl, halogenated -OC 3 -C 6 cycloalkyl and unsubstituted or mono- , di- or trisubstituted by identical or different substituents 5- or 6-membered aromatic heterocycle having 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O and S, in particular from the group
  • At least one compound of general formula (I) is carried out as above, wherein B, A and Y, unless otherwise specified below, have the abovementioned meanings and
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, Cl, CN, OCH 3 , CH 3 , and an unsubstituted or mono-, di- or trisubstituted by identical or different substituents 5- or ⁇ -membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from the group consisting of N, O and S, in particular from the group consisting of Cl, CN, OCH 3 and CH 3 ,
  • R 1 is a radical other than hydrogen, in particular a radical from the group consisting of F, Cl, Br, J, CN, C r C 6 alkyl, OC r C 6 alkyl, halogenated O-Ci-C 6 Alkyl and halogenated C 1 -C 6 -alkyl, more preferably one Residue from the group consisting of Cl, CN, OCH 3 and CH 3 and especially for CN.
  • R 2 is in particular hydrogen.
  • At least one compound of general formula (I) is carried out as above, wherein B, A and Y, unless otherwise specified below, have the abovementioned meanings and
  • R 1 is CN
  • R 2 is hydrogen
  • At least one compound of the general formula (I) is carried out as described above, wherein R 1 , R 2 , B and Y, unless otherwise stated below, have the abovementioned meanings and
  • A is a phenyl ring which is unsubstituted or substituted by one or two identical or different radicals independently selected from the group consisting of halogen, CN, NO 2 , C 1 -C 4 alkoxy, C 1 -C 6 alkoxy-D-C ⁇ alkyl, dC 6 alkyl, NH 2, NH- (C r C 6 alkyl), N (Ci-C6 alkyl) (Ci-C 6 - alkyl), (C 0 -C 6 alkyl) - NH-C 1 -C 6 -alkylene, (C 1 -C 6 -alkyl) (C 1 -C 6 -alkyl) -N-C 1 -C 6 alkylene, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkoxy, -C 6 -haloalkyl, -C 6 - alkylcarbonyl, d-CerHalogenalky
  • substituents on A this is located in the 2-, 3- or 4-position of the phenyl ring.
  • substituents on A these are preferably located in the 2- and the 4-position or in the 2- and the 5-position of the phenyl ring.
  • At least one compound of the general formula (I) is carried out as described above, wherein R 1 , R 2 , B and Y, unless otherwise stated below, have the abovementioned meanings and
  • A is a phenyl ring substituted with one or two identical or different radicals independently selected from the group consisting of fluoro, chloro, CN, NH 2 , CF 3 , CH 3 , C 2 H 5 , nC 3 H 7 , iC 3 H 7 , sec-C 4 H 9 , iso-C 4 H 9 , tert-C 4 H 9 , C (O) CH 3 , SO 2 CH 3 , SO 2 CF 3 , OCF 3 , OCHF 2 , methoxy,
  • Ethoxy, methoxymethyl, N, N-dimethylamino-methyl and N-methylamino-methyl in particular from the group consisting of fluorine, chlorine, methoxy, ethoxy, methoxymethyl, N, N-dimethylamino-methyl and N-methylamino-methyl,
  • A is a phenyl ring substituted with one or two identical or different radicals independently selected from the group consisting of fluoro, chloro, CN, NH 2 , CF 3 , CH 3 , C 2 H 5 , nC 3 H 7 , iC 3 H 7 , sec-C 4 H 9 , iso-C 4 H 9 , tert-C 4 H 9 , C (O) CH 3 , SO 2 CH 3 , SO 2 CF 3 , OCF 3 , OCHF 2 , methoxy,
  • Ethoxy, methoxymethyl, N, N-dimethylamino-methyl and N-methylamino-methyl in particular from the group consisting of fluorine, chlorine, methoxy, ethoxy, methoxymethyl, N, N-dimethylamino-methyl, N-methylamino-methyl, wherein im If a substituent thereof is arranged in the 2-, 3- or 4-position and in the case of two substituents, a substituent in the 2-position and the other are arranged in the 4- or 5-position.
  • At least one compound of the general formula (I) is carried out as described above, wherein R 1 , R 2 , B and Y, unless otherwise stated below, have the abovementioned meanings and
  • A is a phenyl ring substituted with one or two radicals independently selected from the group consisting of 2-fluoro, 4-fluoro, 2-chloro, 4-chloro, 2-methoxy, 2-methyl, 2- Ethyl, 3-methoxy, 4-methoxy, 2-ethoxy, 4-ethoxy, 4-trifluoromethyl, 4-difluoromethoxy, 4-
  • Trifluoromethoxy 4-methyl, 4-ethyl, 4-isopropyl, 4-tert-butyl, 4-acetyl, 4-nitro, 4-cyano, 4-methylsulfonyl, 2-methoxymethyl, 4-amino, 3-N, N -Dimethylamino-methyl and 3-N-methylamino-methyl, in particular from the group consisting of 4-fluoro, 2-chloro, 2-methoxy, 3-methoxy, 4-methoxy, 2-ethoxy, 2-methoxymethyl, 3-N , N-dimethylamino-methyl and 3-N-methylamino-methyl. their tautomeric, enantiomeric and diastereomeric forms, and their prodrugs, as well as the physiologically acceptable salts of said compounds.
  • At least one compound of the general formula (I) is carried out as described above, wherein R 1 , R 2 , B and Y, unless otherwise stated below, have the abovementioned meanings and
  • A is a radical selected from the group consisting of 2-methoxyphenyl, 2-ethoxy-phenyl, 2-ethoxy-4-fluorophenyl, 2-ethoxy-5-methoxyphenyl, 2-chlorophenyl, 3,4- Dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,3-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2-methoxymethyl-phenyl, 3-N, N-dimethylaminomethyl-phenyl, 2-methoxy-3-N, N-dimethylaminomethylphenyl and 2-methoxy-3-N-methylaminomethylphenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4-cyanophenyl, 2-chloro 4-trifluoromethylphenyl, 2-methoxy-4-ethoxyphenyl, 4-chloro-2-flu
  • A is a naphthyl radical, especially a 1-naphthyl radical which is optionally substituted with one or two identical or different radicals that are independently selected from the group consisting of halogen, CN, NO 2, C r C 4 alkoxy, Ci- C 6 alkoxy-C 6 alkyl, C r C 6 alkyl, NH 2, NH- (6 -alkyl), N (Ci-C6 alkyl) (Ci-C6 alkyl), ( C 0 -C 6 -alkyl) -NH-C 1 -C 6 -alkylene,
  • A is a 1-naphthyl radical which is substituted with a radical selected from the group consisting of fluorine and chlorine, the radical preferably being located at the 5-position of the naphthyl radical.
  • Y is a radical selected from the group of the following radicals Y1 to Y24:
  • R is a radical selected from the group of radicals wherein R ⁇ may be substituted by one or two substituents R ⁇ 6 and R ⁇ 7 and R ⁇ 6 and R ⁇ 7 are independently defined as above, and
  • Z is a radical selected from the group of radicals
  • R ⁇ 6 and R ⁇ 8 and R ⁇ 6 and R ⁇ 7 are independently of one another and independently of their occurrence as defined above and R 14 has one of the meanings given above.
  • Y is a radical selected from the group consisting of the following radicals Y1 to Y6 and Y14 to Y17
  • R 2 1 is a 5- or 6-membered, saturated or fully or partially unsaturated heterocycle or aromatic heteroaryl ring having 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle or heteroaryl ring, two or three same or may have different substituents R 2 1 , which are independently of one another and independently of their occurrence selected from the group consisting of the radicals hydrogen, halogen, chlorine, bromine, iodine, fluorine, CN, CF 3 , OCF 3 , NO 2 , OH, OC r C 4 alkyl, C r C 6 alkyl, OC r C 4 haloalkyl, C r C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, NH 2 , N -Oxide,
  • Z is a radical selected from the group consisting of 4-pyridyl, 2-pyridyl, 3-pyridyl, 2-triazinyl, 4-pyrimidinyl, 1, 3-thiazin-2-yl, which have one, two or three identical or different Substituents may be substituted, which are independently selected from the group consisting of the radicals hydrogen, halogen, chlorine, bromine, iodine, fluorine, CN, CF 3 , OCF 3 , NO 2 , OH, or in each case optionally substituted OdC 4 alkyl , C 1 -C 6 -alkyl,
  • OC r C 4 -haloalkyl C 3 -C 7 -cycloalkyl, C r C 6 -haloalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, NH 2 , N-oxides, NH (C r C 6- alkyl) and N (C 1 -C 6 -alkyl) (C 1 -C 6 -alkyl).
  • Z is a radical selected from the group consisting of the radicals
  • Z may additionally be substituted by R 2 12 and / or R 2 13 , wherein
  • Rz 12 is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 -alkyl kiny I, OH, OC r C 4 -
  • Rz 13 is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 -alkynyl, OH, O (C r C 4 - alkyl), OC 0 -C 4 -alkylene-phenyl, NH 2 , NH (C r C 4 -alkyl) or N (CrC 4 -)
  • R 14 is hydrogen, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 -alkynyl or C 0 -C 4 -
  • Alkylene-phenyl is.
  • Z is a radical selected from the group consisting of 4-pyridyl, 2-pyridyl, 3
  • Z is 4-pyridyl which may be substituted by one, two or three identical or different substituents which are independently selected from the abovementioned substituents and in particular from the group consisting of the radicals hydrogen,
  • Z is a radical selected from the group consisting of pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, 2-methyl-pyridin-4-yl, 2-ethoxypyridin-4-yl, 2-fluoro -pyridin-4-yl, 2-chloro-pyridin-4-yl, 3-methylpyridin-4-yl, 3-fluoro-pyridin-4-yl, N-oxopyridin-4-yl, 3,5-dichloropyridine -4-yl, 2-trifluoromethylpyridin-4-yl, 2-isopropylpyridin-4-yl, 2-ethylpyridin-4-yl, 5-cyano-pyridin-4-yl, 1, 3-thiazol-2-yl, 1 , 3,5-triazin-2-yl and 1, 3-pyrimidin-4-yl, in particular from the group consisting of pyridin-4-yl,
  • Z is a radical selected from the group consisting of pyridin-4-yl, 2-methylpyridin-4-yl, 2-ethoxypyridin-4-yl, 2-fluoropyridin-4-yl, 2-chloropyridine 4-yl, 3-methylpyridin-4-yl, 3-fluoropyridin-4-yl, N-oxopyridin-4-yl, 3,5-dichloropyridine-4 yl, 2-trifluoromethylpyridin-4-yl, 2-isopropylpyridin-4-yl, 2-ethylpyridin-4-yl and 5-cyano-pyridin-4-yl, in particular from the group consisting of pyridin-4-yl and 2-yl methyl-pyridin-4-yl.
  • the compounds of the formula (I) according to the invention have a chiral center in the 3-position of the oxindole skeleton (position which carries the radicals Y and A).
  • the compounds of formula (I) are optically active substances.
  • the compounds of the general formula (I) have a further chiral center, for example in the group R y or Z, diastereomers of these compounds exist.
  • the compounds of the formula (I) according to the invention may be present as a mixture of diastereomers or as a mixture of diastereomers in which one of the two diastereomers is enriched or as essentially diastereomerically pure compounds (diastereomeric excess> 90%).
  • the compounds are present as substantially diastereomerically pure compounds.
  • the respective diastereomers may in turn be present as a mixture of enantiomers, for example as a racemate, or as a mixture of enantiomers in which one of the two enantiomers is enriched, or as substantially enantiomerically pure compounds (ee> 90% enantiomeric excess).
  • the respective diastereomers are present as substantially enantiomerically pure compounds. Particular preference is given to compounds which are essentially diastereomerically pure and enantiomerically pure (> 90%, ee> 90%).
  • the general formula (I) therefore also includes diastereomeric and / or enantiomeric forms of the compounds of general formula (I).
  • composition containing at least one compound of general formula I as defined above or according to any one of claims 1 to 21 or a physiologically acceptable salt thereof.
  • the use of at least one compound of the general formula (I) as defined above or a physiologically tolerable salt thereof for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of diabetes insipidus, enuresis nocturna, Incontinence, diseases in which blood coagulation disorders occur and / or for delaying the voiding and / or for the manufacture of a medicament for the treatment and / or prophylaxis of at least one of said diseases.
  • the use of at least one compound of general formula (I) as defined above or a physiologically acceptable salt thereof for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of hypertension, pulmonary hypertension, heart failure , Myocardial infarction, coronary spasm, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), cardiac ischemia, renal system disorders, edema, renal vasospasm, renal cortex necrosis, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, gastrointestinal tract disorders, gastric Vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, vomiting occurring in chemotherapy, and / or motion sickness and / or for the manufacture of a medicament for the treatment and / or prophylaxis of at least one of said diseases provided.
  • PTCA percutaneous transluminal coronary angioplasty
  • a method for the treatment and / or prophylaxis of at least one disease selected from the group consisting of diabetes insipidus, nocturnal enuresis, incontinence, diseases coagulation disorders occurring and delaying voiding in a patient characterized in that the patient is administered an effective amount of at least one compound of general formula (I) as defined above or according to any one of claims 1 to 21 or a physiologically acceptable salt thereof; provided.
  • a method for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the Heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalaemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, vomiting occurring in chemotherapy, and motion sickness in a patient, characterized in that an effective amount of at least one compound of general formula (I) as above or according to any one of claims 1 to 21 or a physiologically acceptable salt thereof is administered to the patient.
  • PTCA percutaneous transluminal coronary angioplasty
  • a method for the treatment and / or prophylaxis of mood disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) as above or according to one of claims 1 to 21 defined or a physiologically acceptable salt thereof is administered.
  • a method for the treatment of anxiety disorders and / or stress-related anxiety disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) as above or according to one of claims 1 to 21 or a physiologically acceptable salt thereof.
  • a method for the treatment of Memory performance disorders and / or Alzheimer's disease in a patient characterized in that the patient is provided an effective amount of at least one compound of general formula (I) as defined above or according to any one of claims 1 to 21 or a physiologically acceptable salt thereof.
  • a method for treating psychosis and / or psychotic disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) as above or according to one of claims 1 to 21 defined or a physiologically acceptable salt thereof is administered.
  • a method for treating Cushing's syndrome in a patient characterized in that the patient defines an effective amount of at least one compound of general formula (I) as above or according to one of claims 1 to 21 or physiologically acceptable salt thereof is administered.
  • a method for the treatment of sleep disorders in a patient characterized in that the patient defines an effective amount of at least one compound of general formula (I) as above or according to one of claims 1 to 21 or a physiologically acceptable Salt of it is administered.
  • a method of inhibiting the development of tolerance to analgesic effects produced by the administration of analgesic agents, such as morphine, in a patient characterized in that the patient is provided with an effective amount of at least one compound of the general formula (I) according to any one of claims 1 to 21 or a physiologically acceptable salt thereof.
  • the above-mentioned patients are preferably mammals, more preferably humans and non-human animals.
  • the following compounds of the abovementioned general formula (I) are particularly preferred: compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 , 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 , 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 , 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 123 to 242 and their physiologically tolerated salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 243 to 362 and their physiologically tolerated salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 363 to 482 and their physiologically tolerable salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 482 to 602 and their physiologically tolerable salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 603 to 722 and their physiologically tolerable salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 843 to 962 and their physiologically tolerated salts.
  • the following compounds of the abovementioned general formula (I) and the physiologically tolerable salts thereof are particularly preferred: compounds of Examples 963 to 1082 and their physiologically tolerated salts.
  • the compounds according to the invention can be present as racemates or as enantiomerically pure or diastereomerically pure compounds.
  • the compounds are present as enantiomerically pure or diastereomerically pure compounds.
  • Physiologically acceptable salts can be formed, for example, with the following anions:
  • Chloride bromide, phosphate, carbonate, nitrate, perchlorate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, glycollate, methanesulfonate, formate, malonate, naphthalene-2-sulfonate, tosylates, salicylate and / or acetate.
  • Other suitable acids are listed, for example, in "Fortitz der Arzneistoffforschung", 1966, Birkhauser Verlag, Vol. 10, p.224-285.
  • alkyl or “alkylene” always include unbranched or branched “alkyl” or “alkylene”.
  • C 1 -C 4 -alkyl in the sense of the description is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or t-butyl.
  • Co-alkylene or (CH 2 ) o in the sense of the description denotes a single bond or hydrogen.
  • alkyl, -C 6 alkyl, C r C 5 alkyl, and C r C 4 -alkyl as defined in the description of a straight or branched saturated hydrocarbon chain having the respectively specified number of carbon atoms, preferably 1 to 6, more preferably 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1
  • Methylbutyl 2-methylbutyl, 1, 2-dimethylpropyl, 1, 1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2, 3-dimethylbutyl, 1, 1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl or 1-ethyl- 2-methylpropyl, preferably methyl, ethyl, propyl, n-butyl or i-butyl.
  • alkylene, C 1 -C 6 -alkylene and C 1 -C 4 -alkylene mean an alkyl group as defined above in which a hydrogen atom is replaced by a bond.
  • aryl, C 6 -C 2 o-aryl and C ⁇ -Cio-aryl in the meaning of the description in each case an aromatic mono-, bi- or polycyclic radical having preferably 6 to 20 carbon atoms, more preferably 6 to 10 carbon atoms and is preferably selected from phenyl, biphenyl, naphthyl, tetrahydronaphthyl, fluorenyl, indenyl and phenanthrenyl, more preferably from phenyl and naphthyl such as 1-naphthyl or 2-naphthyl. Most preferred is phenyl.
  • the aromatic ring is preferably 5- or 6-membered.
  • Hetaryl also includes the aryl-fused derivatives thereof, namely, an aromatic group having preferably 6 to 20 carbon atoms, more preferably 6 to 10 carbon atoms, most preferably phenyl which is fused to this aromatic ring containing at least one heteroatom.
  • Hetaryl may also be selected from an aromatic radical preferably having 6 to 20, more preferably 6 to 10 carbon atoms, most preferably phenyl, having a heterocycloalkyl group fused thereto.
  • the heterocycloalkyl group is as defined above.
  • Hetaryl is preferably selected from 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-thiazolyl, 5 Thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 3-isothiazolyl, 4-isothiazolyl , 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-
  • cycloalkyl, C 3 -C 7 -cycloalkyl and C 3 -C 6 -cycloalkyl in the sense of the description mean a saturated hydrocarbon ring having 3 to 7, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • C 3 -C 7 -cycloalkenyl is a C 3 -C 7 -cycloalkyl as defined above which has one, two, three, four or more double bonds.
  • C 3 -C 7 -heterocycloalkyl is a C 3 -C 7 -cycloalkyl as defined above, with 1, 2, 3 or 4 identical or different heteroatoms selected from the group consisting of N, O and S.
  • C 3 -C 7 -heterocycloalkenyl is in the sense of the description a C 3 -C 7 -cycloalkenyl, as defined above, with 1, 2, 3 or 4 identical or different heteroatoms selected from the group consisting of N, O and S.
  • C 1 -C 6 -haloalkyl is, as described, a C 1 -C 6 -alkyl, as defined above, in which one, several or all of the hydrogen atoms have been replaced by identical or different halogen atoms as defined below.
  • dC 6 haloalkoxy is for the purposes of description, a Ci-C 6 -alkoxy, as defined above, in which one, several or all of the hydrogen atoms by identical or various halogen atoms as defined below have been replaced.
  • acyl and CrC ⁇ -acyl in the sense of the description mean a straight-chain or branched radical -C (OO) -X, unsubstituted or substituted radicals being C 1 -C 8 -alkyl, C 2 -C 5 -alkenyl or C 2 -C 5 Alkynyl, which are as defined above.
  • alkenyl, C 2 -C 6 -alkenyl, C 2 -C 5 -alkenyl and C 2 -C 4 -alkenyl in the sense of the description mean a branched or unbranched hydrocarbon chain containing at least one double bond, having 2 to 6, preferably 2 to 4
  • alkenyl contains one or two double bonds, most preferably one double bond.
  • alkenyl groups are those as mentioned above for alkyl, which groups contain one or two double bonds, such as vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl 2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2 - methyl-3-butenyl, 3-methyl-3-butenyl, 1, 1-dimethyl-2-propenyl, 1, 2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl , 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-
  • alkynyl, C 2 -C 6 -alkynyl, C 2 -C 5 -alkynyl and C 2 -C 4 -alkynyl in the sense of the description mean a branched or unbranched hydrocarbon chain containing at least one triple bond with 2 to 6, preferably 2 to 4
  • alkynyl contains one or two triple bonds, most preferably a triple bond.
  • alkynyl groups are those as mentioned above for alkyl, which groups contain one or two triple bonds, such as ethynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl, 2-methyl 3-butynyl, 1-methyl-2-butynyl, 1, 1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl 2-pentynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4 pentynyl, 4-methyl
  • C 2 -C 6 alkenyloxy in the sense of the description is an oxygen-bonded C 2 -C 6 -alkenyl, which is as defined above.
  • alkylthio, Ci-C 6 alkylthio, C r C 4 -alkylthio and C r C 2 alkylthio mean in the sense of this description is a straight or branched Alkylensulfanylkette containing 1 to 6 carbon atoms and a sulfur atom.
  • the alkylene radical contains from 1 to 4, more preferably 1 or 2 carbon atoms, wherein alkylene is as defined above.
  • Examples of thioalkyl include thiomethyl or thio-tert-butyl.
  • C 1 -C 6 -alkylamino in the sense of the description is a nitrogen-bonded C 1 -C 6 -alkyl, which is as defined above.
  • CrC ⁇ -acylamino is a nitrogen-bonded CrC ⁇ -acyl as defined above.
  • Aryloxy or -O-aryl is an oxygen-bonded aryl as defined above, especially -O-phenyl.
  • 3- to 10-membered carbocycle as used herein means a saturated or partially unsaturated hydrocarbon ring of 3 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexy, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl.
  • Alkylenearyl is an aryl which is bonded via C 1 -C 6 -acyl, more preferably C 1 -C 4 -alkylene and is optionally substituted in the aryl radical, alkylene and aryl being as defined above.
  • Alkylenearyl is in particular in the aryl radical optionally substituted benzyl or phenethyl.
  • aryloxy, Ci-C ⁇ -aryloxy or -O-aryl mean in the sense of the description an oxygen-bonded aryl as defined above, in particular - O-phenyl.
  • Alkylenehetaryl is a hetaryl which is bonded via C 1 -C 6 -, more preferably C 1 -C 4 -alkylene and is optionally substituted in the hetaryl radical, where alkylene and hetaryl are as defined herein.
  • Alkylenehetaryl is preferably optionally substituted -CH 2 -2-pyridyl, -CH 2 -3-pyridyl, -CH 2 -4-pyridyl, -CH 2 -2-thienyl, -CH 2 -3-thienyl, -CH 2 -2 - Thiazolyl, -CH 2 -4-thiazolyl, CH 2 -5-thiazolyl, -CH 2 -CH 2 -2-pyridyl, -CH 2 -CH 2 -3-pyridyl, -CH 2 -CH 2 -4-pyridyl , -CH 2 -CH 2 -2-thienyl, -CH 2 -CH 2 -3-thienyl, -CH 2 -CH 2 - 2-thiazolyl, -CH 2 -CH 2 -4-thiazolyl or -CH 2 -CH 2 -O-thiazoyl.
  • a bicyclic or tricyclic saturated hydrocarbon radical is a bicycloalkyl or tricycloalkyl radical and has from 5 to 18 carbon atoms.
  • the ring system preferably contains 5 to 12, more preferably 6 to 10, carbon atoms.
  • the ring system preferably contains 6 to 16, more preferably 6 to 12 carbon atoms.
  • Examples of a bicycloalkyl group include indanyl, camphyl and norbornyl.
  • Examples of a tricycloalkyl radical include adamantyl.
  • Halogen is a halogen atom selected from fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine.
  • Alkyl substituted with halogen denotes an alkyl radical as defined above which is partially or completely substituted by fluorine, chlorine, bromine and / or iodine, eg CH 2 F, CHF 2 , CH 2 Cl, 2-fluoroethyl, 2-chloroethyl, 2,2,2-trifluoroethyl.
  • substituted C 1 -C 4 -alkyl in the context of the present invention means that some or all of the hydrogen atoms of the radical "C 1 -C 4 -alkyl" have been replaced by identical, different or partially identical and partly different substituents other than hydrogen. The maximum possible number
  • Substituents are given by the number of hydrogen atoms.
  • the preferred number of substituents is one, two, three or four substituents.
  • Preferred substituents are halogen, C r C 6 alkyl, OC r C 6 alkyl, C 3 -C 7 cycloalkyl, C r C 6 - haloalkyl, O-Ci-C 6 haloalkyl or C 6 -C 0 -aryl ,
  • substituents include: halogen, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NO 2 , NH 2 , OH, COOH, in each case branched or unbranched, optionally substituted C r C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-Ce-alkylene-O-Ci-Ce-alkyl or C r C 6 thioalkyl, OC C4alkyl, N (dC 4 alkyl) 2, NH (C r C 4 alkyl), aryl, -O-aryl, C r C 4 - alkylene-O-aryl, NHCO-C r C 4 alkyl, NH-SO 2 -C r C 4 alkyl, CO-Ci -4 alkyl, SO 2 - -C 4 - alkyl, optionally substituted in the aryl radical NHCO-aryl, NHSO 2 -aryl
  • N is (dC 4 alkyl) 2 as defined in the specification for N (C r C 4 alkyl) (Ci-C 4 alkyl), wherein the two residues (C r C 4 alkyl) may be the same or different
  • Co-C ⁇ -alkyl is hydrogen or CrC ⁇ -alkyl.
  • the compounds of the present invention are effective after administration by various routes (e.g., intravenously, intramuscularly, orally), especially orally.
  • the compounds of the invention show good affinity for vasopressin
  • vasopressin receptor subtypes V1a and V1b for example the vasopressin receptor subtypes V1a and V1b. Since the various vasopressin receptors transmit very different effects of the vasopressin (M. Thibonnier, Exp.Opin., Invest. Drugs 1998, 7 (5), 729-740; Serradeil-Le GaI, C, et al .; Prog Brain Res. 2002; 139: 197-210), it is of particular importance to selectively obtain effects on, for example, a vasopressin receptor so as to obtain the desired effect without at the same time causing significant side effects. For example, vasopressin mediates via the receptor V2, effects on the kidney and its function and this would be undesirable in a possible treatment of CNS disorders.
  • the compounds according to the invention have the advantage of having very good affinities for the desired receptors, such as the vasopressin receptors V1 b and V1a, and at the same time having an improved selectivity with respect to the other receptors, such as V2.
  • Preferred compounds of the general formula (I), their salts, their prodrugs or their N-oxides are distinguished by a binding affinity Ki to the vasopressin receptor subtype V1 b of less than about 500 nM, in particular ⁇ 50 nM. Particular preference is given to compounds of the formula (I) having a Ki of less than or equal to 2O nM.
  • Preferred compounds of general formula (I), their salts, their prodrugs or their N-oxides, are further characterized by having a selectivity to the vasopressin receptor subtype V1b towards at least one of the closely related vasopressin / oxytocin receptor subtypes (e.g. Vasopressin V1 a, vasopressin V2 and / or oxytocin).
  • the selectivity expressed as the ratio of Ki values, e.g. Ki (VI a) / Ki (V1 b) or Ki (V2) / Ki (V1 b) is usually> 1, often> 5, in particular> 10 and especially> 20.
  • Preferred compounds of general formula (I), their salts, their prodrugs or their N-oxides are further characterized by having improved metabolic stability.
  • the metabolic stability of a compound may be determined by incubating a solution of this compound with liver microsomes from certain species (e.g., rat, dog or human) and determining the half-life of the compound under these conditions (RS Obach, Curr Opin Drug Discov Devel. 2001, 4, 36-44). It can be concluded from greater half-lives on improved metabolic stability of the compound.
  • the stability in The presence of human liver microsomes is of particular interest as it allows prediction of metabolic degradation of the compound in the human liver. Compounds with increased metabolic stability are therefore likely to degrade more slowly in the liver as well. The slower metabolic breakdown in the liver usually leads to higher and / or longer-lasting
  • improved metabolic stability can lead to increased bioavailability after oral administration, since the compound undergoes less metabolic degradation in the liver (so-called "first pass effect") after absorption in the intestine.An increased oral bioavailability may be due to increased concentration (level of action ) of the compound lead to a better efficacy of the compound of formula I after oral administration.
  • the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of diseases in which the course of the disease depends, at least in part, on vasopressin, i. Diseases that show an elevated level of vasopressin or oxytocin, which may contribute indirectly or directly to the clinical picture.
  • vasopressin i. Diseases that show an elevated level of vasopressin or oxytocin, which may contribute indirectly or directly to the clinical picture.
  • the present invention provides the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
  • diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
  • the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of the following diseases: hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, renal cortex necrosis, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, gastrointestinal tract disorders, gastric
  • diseases hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, renal cortex necrosis, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, gastrointestinal tract disorders, gastric
  • PTCA percutaneous transluminal coronary angioplasty
  • the compounds of the present invention may also be used to treat various vasopressin-dependent or oxytocin-dependent disorders that have centrally nervous causes or changes in the hypothalamic pituitary adrenal axis (HPA), for example, in affective disorders such as depressive disorders and bipolar disorders.
  • HPA hypothalamic pituitary adrenal axis
  • affective disorders such as depressive disorders and bipolar disorders.
  • HPA hypothalamic pituitary adrenal axis
  • the compounds of the invention can be used for the treatment of anxiety disorders and stress-related anxiety disorders, such as generalized anxiety disorders, phobias, post-traumatic anxiety disorders, panic anxiety disorders, obsessive-compulsive anxiety disorders, acute stress-related anxiety disorders and social phobia.
  • the compounds of the invention can also be used for the treatment of memory disorders, Alzheimer's disease, psychosis, psychotic disorders, sleep disorders and / or the Cushing syndrome.
  • the present invention also relates to pharmaceutical compositions containing an effective dose of a compound of the invention or a pharmaceutically acceptable salt thereof and suitable excipients.
  • excipients are chosen according to the pharmaceutical form and the desired mode of administration.
  • the compounds of the general formula I according to the invention or optionally suitable salts of these compounds can be used for the preparation of pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration and animals or humans in uniform administration forms, mixed with conventional pharmaceutical carriers, for the prophylaxis or treatment of the above disorders or diseases.
  • the appropriate unitary forms of administration include forms for oral administration, such as tablets, gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms of subcutaneous, intramuscular or intravenous administration, and forms of rectal administration.
  • the compounds of the invention can be used in creams, ointments or lotions.
  • the dose of the active principle may vary between 0.01 and 50 mg per kg body weight and per day.
  • Each unit dose may contain from 0.05 to 5000 mg, preferably from 1 to 1000 mg, of the active ingredient in combination with a pharmaceutical carrier. This unit dose may be administered 1 to 5 times a day so that a daily dose of 0.05 to 25,000 mg, preferably 1 to 5,000 mg, is administered.
  • a solid composition is prepared in the form of tablets, the main ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
  • a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
  • the tablets may be coated with sucrose, a cellulose derivative or other suitable substance or otherwise treated to have sustained or delayed activity and to continuously release a predetermined amount of the active principle.
  • a preparation in the form of gelatin capsules is obtained by mixing the active ingredient with an extender and incorporating the resulting mixture into soft or hard gelatin capsules.
  • a preparation in the form of a syrup or elixir or for administration in the form of drops may contain active ingredients together with a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
  • a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
  • the water-dispersible powders or granules may contain the active ingredients mixed with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidones, as well as sweeteners or flavoring agents.
  • Rectal administration is achieved by using suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
  • Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or sterile and injectable solutions containing pharmacologically acceptable dispersants and / or wetting agents, for example, propylene glycol or polyethylene glycol.
  • the active principle may also be formulated as microcapsules or centrosomes, if appropriate with one or more carriers or additives.
  • compositions according to the invention may contain other active principles which may be useful for the treatment of the above-mentioned disorders or diseases.
  • the present invention thus further relates to pharmaceutical compositions in which several active principles are present together, at least one of which is a compound of the invention.
  • the compounds according to the invention are antagonists of the so-called receptors of the vasopressin oxytocin family. Such compounds can be tested in suitable assays which detect the affinity for a receptor, the affinity constant Ki being a measure of the potency of the compounds and a smaller value represents a greater potency.
  • the compounds of the invention have been tested, for example, for their receptor affinity for the vasopressin receptor subtypes V1b, V1a, V2 and / or the oxytocin receptor.
  • Isolates II are either commercially available or have been prepared analogously to methods described in the literature (Advances in Heterocyclic Chemistry, AR Katritzky and AJ Boulton, Academic Press, New York, 1975, 18, 2-58, J. Brazil Chem Soc., 12, 273-324, 2001).
  • the 3-hydroxy-oxindoles (III) can be converted into the compounds (V) which carry a leaving group (LG) in the 3-position, the leaving group (LG) being customary leaving groups, for example halides, mesylate or tosylate can.
  • the intermediate (V) may be prepared by treating the alcohol (IV) with thionyl chloride in the presence of a base such as pyridine.
  • the alcohols (IV) can be converted to the mesylate by reaction with methanesulfonyl chloride in the presence of a base such as triethylamine.
  • the compounds (V) are then reacted with suitable amines to give the analogous amine compounds (VI).
  • substitution reactions with amines in the presence of a base such as ⁇ /, ⁇ / -diisopropylethylamine can yield the analogous 3-amino-oxindoles (VI).
  • the amine compound (VI) thus obtained can then be converted into the corresponding sulfone compound by treatment with sulfonyl chlorides R'-SC> 2 Cl after deprotonation with a strong base such as, for example, potassium tert-butoxide or sodium hydride in DMF (VIII).
  • the introduction of the 5-cyano group can also be carried out in a later synthesis step, for example by replacing the 5-iodo substituent in the compound (X) to obtain the corresponding 5-cyano compound (VI) according to known procedures ( as described above, for example).
  • the exchange at the 5-position of iodine for cyano can also take place at the stage of compound (XI) to give compound (VIII) (see Synthetic Scheme 2).
  • Compounds I wherein B is 2-aminophenylsulfonyl can be prepared, for example, starting from compound X by reacting X with commercial 2-nitrobenzenesulfonic acid chloride and reducing (e.g., by catalytic hydrogenation) the nitro group in the resulting compound I.
  • reaction a) is carried out analogously to the method described in J. Med. Chem. 2001, 36, 809-828.
  • reaction b) is carried out in analogy to the method described in Synthesis 1986, 852.
  • the reactions are shown by way of example in Schemes 4a and 4b.
  • One of the preferred radicals Y is an optionally substituted pyridin-4-yl-piperazin-1-yl.
  • the corresponding, optionally substituted pyridin-4-yl-piperazine or its N-oxide can be prepared according to the method described in Chem. Pharm. Bull. 2001, 41, 1314-1320.
  • the synthesis of pyridin-4-yl-piperazine is shown in Scheme 5:
  • the compounds according to the invention have a chiral center in the 3-position of the oxindole skeleton.
  • the separation of the enantiomers may be at the stage of the final products or, as shown in Scheme 7, also on a precursor, e.g. the compound VI.
  • the compound VI is converted into an optically active urea compound.
  • the chiral separation of the enantiomers with L-leucineol can be carried out, for example, as described in WO 03/008407 on pages 26 and 27 and 79 and 80.
  • the separation of the enantiomers can be performed by HPLC on chiral separation columns, e.g. Separation column: Chiracel OD 250x4.6x10mm; Eluate: hexane: EtOH: NEt3 850: 150: 1.
  • Example 1 5-Chloro-3- (2-methoxy-phenyl) -3- (4-pyridin-3-yl-piperazin-1-yl) -1,3-dihydro-indol-2-one
  • a solution of 5-chloro 3-hydroxy-3- (2-methoxy-phenyl) -1,3-dihydro-indol-2-one (WO 2005/030755, 0.50 g, 1.73 mmol) in dichloromethane (40 mL) was added under pyridine-cooling with pyridine ( 0.18 mL, 2.24 mmol) and thionyl chloride (0.16 mL, 2.24 mmol) and stirred at 0 ° C. for 45 min.
  • the following compounds 2 to 122 were prepared.
  • the compounds were purified by preparative reversed-phase HPLC (eluent: gradient of 10% to 80% acetonitrile in water, 0.1% trifluoroacetic acid or 0.2% acetic acid as modulator) and, if they contain a basic nitrogen in the molecule, as Trifluoroacetic acid salts or acetic acid salts.
  • variables R 1 , R 2 , A, B and Y are each independently selected from the group consisting of
  • R 1 CN in position 5 (CN, see Tables 1 and 8), methoxy in position 5 (OMe, see Tables 2 and 5), methyl in position 5 (Me, see Tables 3 and 6) and chlorine in 5-position (C1, see Tables 4 and 7);
  • A 2-ethoxyphenyl (2-0Et-Ph), 2-ethoxy-5-methoxyphenyl (2-OEt-5-OMe-Ph), 2-ethoxy-5-methylphenyl (2-OEt-5-Me-Ph) and 2-ethoxy-4-fluoro-phenyl (2-OEt-4-F-Ph);
  • B 4-methoxyphenyl (4-OCH 3 -Ph), 4-cyanophenyl (4-CN-Ph) and 2,4-dimethoxyphenyl (2,4-di-OMe-Ph).
  • Y Y1, Y2, Y3, Y4, Y5, Y6, Y14, Y15, Y16 and Y17 with the following meanings:
  • each Z is 4-pyridinyl (in Tables 1 to 4) and 2-methyl-pyridin-4-yl (in Tables 5 to 8).
  • test substances were 'dissolved 2 M in DMSO and DMSO to 5x10 "in a concentration of 10 further diluted 9 M 4 M to 5x10" These DMSO solutions were diluted with assay buffer 1:.. Diluted 10 In the test batch, the substance concentration was again 1: 5 diluted.
  • Membrane preparation CH0-K1 cells stably expressed with human vasopressin V1 b receptor (clone 3H2) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron homogenizer at medium position 2x10 seconds and then 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
  • protease inhibitors Roche complete Mini # 1836170
  • the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
  • Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
  • membranes 50 ug / ml protein in incubation buffer
  • CHO-K1 cells with stably expressed human V1 b receptors (cell line hV1 b_3H2_CHO) with 1, 5 nM 3 H-AVP (8-Arg vasopressin , PerkinElmer # 18479) in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or additionally incubated with increasing concentrations of test substance (displacement experiment).
  • Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). All determinations were made as triplicate determinations.
  • the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
  • the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • the binding parameters were calculated by nonlinear regression in SAS.
  • the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem., 107, 220-239 (1980)).
  • the Kd value of 3 H-AVP to the recombinant hV2 receptors is 0.4 nM and was used to determine the Ki value.
  • Vasopressin V1a receptor binding test
  • test substances were dissolved in a concentration of 10 "2 M in DMSO.
  • concentration of 10 "2 M in DMSO was carried out in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4).
  • Membrane preparation CHO-K1 cells stably expressed with human vasopressin V1 a receptor (clone 5) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron homogenizer at medium position 2x10 seconds and then centrifuged for 1 h at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
  • protease inhibitors Roche complete Mini # 1836170
  • Binding test The binding test was carried out in accordance with the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)). Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4. In the assay (250 ⁇ l), membranes (20 ⁇ g / ml protein in incubation buffer) of CHO-K1 cells with stably expressed human V1a receptors (cell line hV1a_5_CHO) were incubated with 0.04 nM 125 I-AVP (8-arg-vasopressin, NEX 128). in
  • Incubation buffer 50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4 (total binding) or additionally incubated with increasing concentrations of test substance (displacement experiment). Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). Triple determinations were made.
  • the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials. The liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • the binding parameters were calculated by nonlinear regression in SAS.
  • the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem., 107, 220-239 (1980)).
  • the Kd value of 125 I -AVP to the recombinant hV1a receptors was determined in saturation experiments.
  • a Kd value of 1.33 nM was used to determine the Ki value.
  • test substances were 'dissolved 2 M in DMSO and in DMSO at 10 "in a concentration of 10 further diluted 9 M 3 M to 5x10" Further dilution of these DMSO solutions were suspended in incubation buffer (50 mM Tris, 10 mM MgCl. 2 , 0.1% BSA, pH 7.4).
  • CHO-K1 cells stably expressed with human vasopressin V2 receptor (clone 23) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron homogenizer at medium position 2x10 seconds and then for 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
  • the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
  • Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
  • membranes 50 ⁇ g / ml protein in incubation buffer
  • CHO-K1 cells with stably expressed human V2 receptors (cell line hV2_23_CHO) with 1-2 nM 3 H-AVP (8-Arg vasopressin, Perkin Elmer # 18479) in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or additionally incubated with increasing concentrations of test substance (displacement experiment).
  • total binding 50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4
  • the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
  • the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • the binding parameters were calculated by nonlinear regression in SAS.
  • the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem., 107, 220-239 (1980)).
  • the Kd value of 3 H-AVP to the recombinant hV1b receptors is 2.4 nM and was used to determine the Ki value.
  • Substances The substances were dissolved in a concentration of 10 "2 M or 10" 3 M in DMSO and diluted with incubation buffer (50 mM Tris, 10 mM MgCl 2, 0.1% BSA, pH 7.4).
  • Confluent HEK-293 cells with transiently expressed recombinant human oxytocin receptors were centrifuged at 750 xg for 5 minutes at room temperature. The residue was dissolved in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH 7.4 and Roche Complete protease inhibitor) was added and 20 minutes at 4 0 C subjected to osmotic shock. Thereafter, the lysed cells were centrifuged at 750 xg for 20 minutes at 4 0 C, the residue taken up in incubation buffer, and aliquots of 10 7 cells / ml. The aliquots were frozen until use at -8O 0 C.
  • Reaction rate of 0.250 ml was composed of 2 to 5 ⁇ 10 4 recombinant cells, 3-4 nM 3 H-oxytocin (PerkinElmer, NET 858) in the presence of test substance (inhibition curve) or only incubation buffer (total binding). The nonspecific binding was with 10 "6 M oxytocin (Bachem AG, H2510) is determined. Triplicates were used. Bound and free radioligand were separated by filtration under vacuum using Whatman GF / B glass fiber filters using a Skatron cell harvester 7000. The bound radioactivity was by liquid scintillation measurement in a Tricarb Beta Counter, Model 2000 or 2200CA (Packard).
  • the binding parameters were calculated by nonlinear regression analysis (SAS), analogous to the program LIGAND by Munson and Rodbard (Analytical Biochem 1980, 107: 220-239).
  • SAS nonlinear regression analysis
  • the Kd value of 3 H-oxytocin to the recombinant hOT- Receptor is 7.6 nM and was used to determine the Ki value.
  • test substances were investigated on CHO-K1 cells stably transfected with the human V1 b receptor.
  • CHO-K1 cells stably transfected with the human V1 b receptor.
  • the culture medium consisted of DMEM / Nut Mix F12 with Glutamax I (Invitrogen), 10% fetal calf serum, 100 units / ml penicillin, 100 ⁇ g / ml streptomycin and 800 ⁇ g / ml geneticin.
  • the next day, the cells were washed with culture medium and loaded with a fluorescent dye for calcium according to the manufacturer's instructions (Ca ++ Plus Assay Kit, Molecular Devices). The loading of the cells was carried out in the presence of Probenzid (1 vol%).
  • the test substances were with DMEM / Nut Mix F12 with Glutamax I (Invitrogen), 10% fetal calf serum, 100 units / ml penicillin, 100 ⁇ g / ml streptomycin and 800 ⁇ g
  • the affinities for the human vasopressin receptor V1b were measured in accordance with the above test and the affinity constants (Ki) were determined.
  • the V1 b receptor affinity of selected compounds is listed (+++ means ⁇ 50 nM, ++ means 50-50O nM).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés d'oxindol de formule générale (I), dans laquelle les substituants R1, R2, A, B et Y sont tels que définis à la revendication 1, des médicaments les contenant et leur utilisation pour le traitement prophylactique et/ou thérapeutique de maladies dépendant de la vasopressine et/ou de l'oxytocine.
EP07802882A 2006-08-26 2007-08-24 Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine Withdrawn EP2066657A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006040915A DE102006040915A1 (de) 2006-08-26 2006-08-26 Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US95859107P 2007-07-06 2007-07-06
PCT/EP2007/058839 WO2008025735A1 (fr) 2006-08-26 2007-08-24 Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine

Publications (1)

Publication Number Publication Date
EP2066657A1 true EP2066657A1 (fr) 2009-06-10

Family

ID=39078826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07802882A Withdrawn EP2066657A1 (fr) 2006-08-26 2007-08-24 Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine

Country Status (9)

Country Link
US (1) US8431567B2 (fr)
EP (1) EP2066657A1 (fr)
JP (1) JP2010501620A (fr)
CN (1) CN101528736A (fr)
CA (1) CA2670271A1 (fr)
DE (1) DE102006040915A1 (fr)
MX (1) MX2009002133A (fr)
TW (1) TW200823195A (fr)
WO (1) WO2008025735A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486931B2 (en) * 2007-03-02 2013-07-16 Abbott Gmbh & Co. Kg Substituted oxindole compounds
EP2227463B1 (fr) 2007-12-27 2016-08-17 AbbVie Deutschland GmbH & Co KG Dérivés substitués d'oxindole et leur utilisation pour le traitement de maladies dépendant de la vasopressine
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
EP2655360B1 (fr) 2010-12-21 2016-04-20 Bayer Intellectual Property GmbH Procédé de préparation d'oxindoles n-sulfonyle substitués
WO2012084855A2 (fr) 2010-12-21 2012-06-28 Bayer Cropscience Ag Procédé de préparation d'oxindoles substitués par triazinyle
WO2015173393A1 (fr) * 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Composés d'oxindole portant un substituant spiro lié à un atome d'azote, et leur utilisation pour le traitement de maladies liées à la vasopressine
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
WO2022126179A1 (fr) * 2020-12-14 2022-06-23 The University Of Sydney Modulateurs du récepteur de l'oxytocine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
DE102004033834A1 (de) * 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
WO2006080574A1 (fr) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. Compose 1,3-dihydro-2h-indole-2-one et compose pyrrolidine-2-one condense avec un heterocycle aromatique
US8486931B2 (en) * 2007-03-02 2013-07-16 Abbott Gmbh & Co. Kg Substituted oxindole compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008025735A1 *

Also Published As

Publication number Publication date
US20090318406A1 (en) 2009-12-24
MX2009002133A (es) 2009-03-09
CN101528736A (zh) 2009-09-09
US8431567B2 (en) 2013-04-30
TW200823195A (en) 2008-06-01
CA2670271A1 (fr) 2008-03-06
JP2010501620A (ja) 2010-01-21
DE102006040915A1 (de) 2008-03-20
WO2008025735A1 (fr) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008025735A1 (fr) Dérivés d'oxindol substitués et leur utilisation comme ligands du récepteur de la vasopressine et/ou de l'oxytocine
EP1831197A2 (fr) Derives d'oxindol substitues, agents pharmaceutiques les contenant, et leur utilisation
WO2006100082A2 (fr) Derives d'oxindole substitues, medicaments contenant ces derives et leur utilisation
EP2231644B1 (fr) Dérivés oxindoliques disubstitués en positions 5 et 6 et leur utilisation pour la préparation d'un medicament pour le traitement de maladies liées à la vasopressine
DE69926542T2 (de) Aminopyrazolderivate
EP2231645B1 (fr) Dérivés oxindoliques substitués par halogène en position 5 et leur utilisation pour la préparation d'un medicament pour le traitement de maladies liées à la vasopressine
DE60214990T2 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
DE102005014904A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102004033834A1 (de) Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
KR102499522B1 (ko) 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체
WO2006032541A1 (fr) Derives d'indole en tant qu'inhibiteurs de l'adenylate cyclase soluble
DE69922594T2 (de) Indazol-Derivate als 5-HT1F agonists
EP1802572B1 (fr) Derives d'indole en tant qu'inhibiteurs de l'adenylate cyclase soluble
WO2009083559A1 (fr) Dérivés substitués d'oxindole et leur utilisation pour le traitement de maladies dépendant de la vasopressine
WO2009071691A2 (fr) Dérivés oxindoliques et leur utilisation comme médicament
DE1695228A1 (de) Verfahren zur Herstellung von aromatischen Verbindungen
KR20210019990A (ko) 트로포미오신 수용체 키나아제 억제제 및 그 제조 방법과 응용
DE102005015957A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014628A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2007063123A1 (fr) Derives d'oxindole substitues, medicaments les contenant et leur utilisation
HUE030859T2 (en) Substituted 6-amino-nicotinamides bearing an OH-containing group as modulators of KCNQ2 / 3
BR112018015851B1 (pt) Composto, e, medicamento
SA108290827B1 (ar) مشتقات ثنائية الحلقة من أجل الاستخدام في علاج الحالات المتعلقة بمستقبل الأندروجين - 155

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HORNBERGER, WILFRIED

Inventor name: UNGER, LILIANE

Inventor name: LUBISCH, WILFRIED

Inventor name: WERNET, WOLFGANG

Inventor name: HUTCHINS, CHARLES, W.

Inventor name: NETZ, ASTRID

Inventor name: OOST, THORSTEN

Inventor name: GENESTE, HERVE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

DAX Request for extension of the european patent (deleted)
18D Application deemed to be withdrawn

Effective date: 20120301